Preview of DNA
Preview of DNA for genetics unit!From:Dana DossViews:1 0ratingsTime:04:12More inEducation

View post:
Preview of DNA - Video

Recommendation and review posted by Bethany Smith

Alumni Video - Marc Hammarlund
Marc Hammarlund is an alumni of the University of Utah Molecular Biology program. He graduated with his PhD in Biology and is currently an Assistant Professor of Genetics at Yale University.From:UofUBiosciencePhDViews:2 0ratingsTime:02:43More inEducation

Here is the original post:
Alumni Video - Marc Hammarlund - Video

Recommendation and review posted by Bethany Smith

Drosophila, baby! - Genetics Call Me Maybe Parody
Drosophila, BabyFrom:localsurfacousticViews:9 0ratingsTime:03:16More inFilm Animation

Read more here:
Drosophila, baby! - Genetics Call Me Maybe Parody - Video

Recommendation and review posted by Bethany Smith

Ahmanson Lectures on Creation
The Ahmanson Lectures on Creation bring facts, historical evidence, philosophical and scientific investigations to Christianity. Taught during Saddleback Church #39;s Apologetics Weekend, five professionals in the field, some atheists turned Christian, reenergize our faith as they teach the evidence of Christianity in science, nature, genetics and living cells, the origin of the universe, and more. In this first message in the Ahmanson Lectures on Creation, we hear from Lee Strobel. Former award winning legal editor for the Chicago Tribune, author of several books including The Case for Christ and The Case for a Creator, former Saddleback pastor and former atheist, Strobel teaches a message on three areas of science that give powerful evidence to God #39;s existence.From:SaddlebackResourcesViews:0 0ratingsTime:03:51More inNonprofits Activism

View original post here:
Ahmanson Lectures on Creation - Video

Recommendation and review posted by Bethany Smith

Pancreatic Cancer Awareness Day - Prevention Genetics, Dr. Fay Kastrinos (9)
Dr. Kastrinos was the ninth in a series of speakers who participated in the November 3rd Annual Pancreatic Cancer Awareness Day. Dr. Kastrinos describes the role of prevention and genetics in the detection of pancreatic cancer. For more information about the Pancreas Center visit pancreasmd.org, call 212-305-9467, or email info@columbiasurgery.org.From:ColumbiaSurgeryViews:1 0ratingsTime:06:39More inEducation

See the article here:
Pancreatic Cancer Awareness Day - Prevention

Recommendation and review posted by Bethany Smith

Professor Robin Feldman on Myriad
The US Supreme Court has granted review in Association for Molecular Pathology v. Myriad Genetics on the specific question, "Are human genes patentable?" UC Hastings College of the Law Professor Robin Feldman discusses that question, plus the "quartet of Supreme Court patent law decisions" that she believes may soon become a "quintet." Professor Robin Feldman #39;s work is widely regarded as some of the most influential scholarship in the field of patent law. She offered significant commentary to multiple media outlets during the Apple v. Samsung patent lawsuit and its recent groundbreaking decision. Her latest book, Rethinking Patent Law, was published by Harvard University Press in 2012 and explains patent bargaining. Her bio and publications are available at tinyurl.comFrom:uchastingslawViews:1 0ratingsTime:05:49More inEducation

Read more here:
Professor Robin Feldman on Myriad - Video

Recommendation and review posted by Bethany Smith

Bronson-"Man With a Camera" shows "Hard Times" moves
Charles Bronson forced to box for his life in the TV show, Man With a Camera. On Netflix streaming. Notice the tight, triple cross combo is the same as the one he would use years later in Hard Times. This is second season Man With A Camera. Where, like Wild Wild West , they figured out it was a good idea for Bronson to have his shirt off. The first season he had a single episode with his shirt off. It #39;s genetics. The guy Bronson is boxing probably works just as hard as Bronson staying fit.From:plazpasticViews:0 0ratingsTime:02:08More inFilm Animation

Read more:
Bronson-"Man With a Camera" shows "Hard Times" moves - Video

Recommendation and review posted by Bethany Smith

Monster Dab @ the Kush Expo in LA
Taking a monster dab during the Kush Expo at LA Center Studios in Los Angeles (October 2012. Got a chance to hang out with the guys from Kush Connection.. HTCC Winners Master Yoda. Fantastic genetics, clean- well processed hash. These guys are what is up in LA.. check them out on W. Pico Blvd. ( Had to re-post due to issues with earlier account).From:theGLReviewViews:0 0ratingsTime:00:58More inPeople Blogs

Read the rest here:
Monster Dab @ the Kush Expo in LA - Video

Recommendation and review posted by Bethany Smith

Lot5B Flying H Genetics
From:Katina CosterisanViews:3 0ratingsTime:01:05More inPeople Blogs

Here is the original post:
Lot5B Flying H Genetics - Video

Recommendation and review posted by Bethany Smith

Lot5A Flying H Genetics
From:Katina CosterisanViews:0 0ratingsTime:00:55More inPeople Blogs

See the original post here:
Lot5A Flying H Genetics - Video

Recommendation and review posted by Bethany Smith

Lot 25. Binnia Celine - Auctions Plus Progressive Genetics Sale
Lot 25 Binnia Celine - Auctions Plus Progressive Genetics Sale Well bred mare, solid foundation bloodlines. Good sensible low maintenance mare, easy breeder. All of her foals are quiet, with good conformation. Joined to top campdrafter, Chevin Ivory ASHS 140917 More Information: localmedia.auctionsplus.com.au http://www.landmark-classic.com.au Sale on Auctions Plus 10th December 2012From:LandmarkEquineViews:0 0ratingsTime:01:00More inSports

See the original post here:
Lot 25. Binnia Celine - Auctions Plus Progressive Genetics Sale - Video

Recommendation and review posted by Bethany Smith

Lot 14. Scroll Dee Maggy - Auctions Plus Progressive Genetics Sale
Lot 14. Scroll Dee Maggy - Auctions Plus Progressive Genetics Sale Exceptional broodmare that is real easy to breed Maggy has a filly foal at foot by Campdraft and Challenge winning sire Destination Unknown, AQHA Q-45790 ASHS C2-160782 (Acres Destiny/Spinnis Golddust) and preg tested in foal again to the same. An outstanding opportunity to purchase a proven broodmare as a 3 in 1 package, with her 2007 filly selling for $12500 -- Landmark Classic Sale and her 2009 filly selling for $7500 -- Fountain of Youth National Yearling Sale. This mare is a sound investment for anyone #39;s breeding program. More Information: Dale Lyons Mobile: 0428 228 819 localmedia.auctionsplus.com.au http://www.landmark-classic.com.au Sale on Auctions Plus 10th December 2012From:LandmarkEquineViews:0 0ratingsTime:00:53More inSports

Here is the original post:
Lot 14. Scroll Dee Maggy - Auctions Plus Progressive Genetics Sale - Video

Recommendation and review posted by Bethany Smith

Cute Dog Plays Tug of War Video
Cute Dog Plays Tug of War Video. Khloe wants her Soccer Ball back and will not give up until she wins, she loves her Soccer Ball! Give Khloe a Thumbs Up for being a COOL DOG! Some info on Khloe #39;s Breed, Lhasa-Poo: Breed Group: Mixes and More Height: Varies Weight: 10 to 20 pounds Life Span: 12 to 15 years The Lhasapoo is a cross between a Lhasa Apso and a Poodle, usually a Miniature Poodle. He may have the curly coat of a Poodle or the long, straight coat of a Lhasa Apso, but he always has a cute, alert face, and sturdy body. The Lhasapoo can come in a multitude of solid colors or in a particolor pattern (a color plus white). The Lhasapoo is a crossbreed. Opening your heart and home to a crossbreed is like opening a beautifully wrapped package on your birthday: you never know what #39;s going to be inside. It #39;s often assumed that a crossbreed will combine the best of two or more breeds, but genetics doesn #39;t always work that way. The way genes combine and express themselves is not necessarily in a breeder #39;s control, even less so when two breeds are crossed. That #39;s something to keep in mind before you lay down lots of money for a dog that you have been assured will be hypoallergenic or healthier than a purebred. At their best, Lhasapoos are friendly and affectionate, although some may have the suspicious nature of the Lhasa Apso, whose original purpose was to serve as a temple watchdog. Lhasapoos generally weigh 10 pounds to 20 pounds, making them a comfortable size for most ...From:Mad4ClipsViews:2 1ratingsTime:01:23More inPets Animals

Excerpt from:
Cute Dog Plays Tug of War Video - Video

Recommendation and review posted by Bethany Smith

The Ediculture Course Session 10 Part 2 - SEED SAVING AND GENETICS.wmv
The Ediculture Course Session 10 Part 2 - SEED SAVING AND GENETICS As well as demonstrating competence in all the aspects of growing described on the course and providing potential to secure your food supply in perpetuity, seed saving challenges trends towards uniformity and monopolising nature. Growers need the opposite of commercial qualities - Diversity and local Adaptation, Extended cropping periods and planning for Permanence. This is the tip of the pinnacle of human achievement throughout history! Taste the food of the gods!From:edicultureViews:0 0ratingsTime:39:07More inEducation

Continue reading here:
The Ediculture Course Session 10 Part 2 - SEED SAVING AND GENETICS.wmv - Video

Recommendation and review posted by Bethany Smith

Stock Science: Mendelian Genetics
Mr. Stockton talks about Mendel #39;s Pea Plants and the basics of "particulate" genetics.From:Bill StocktonViews:0 0ratingsTime:10:00More inEducation

Read the original post:
Stock Science: Mendelian Genetics - Video

Recommendation and review posted by Bethany Smith

Research commissioned by Marks & Spencer has found that the use of New Zealand sheep genetics could offer sustainability benefits for UK sheep farmers.

The work, which was jointly conducted by the Agri-Food & Biosciences Institute (AFBI) and the College of Agriculture, Food and Rural Enterprise (CAFRE), investigated the merits of using Highlander and Primera sheep breeds in UK sheep flocks to maximise value in the supply chain through increased lamb output and reduced production and processing costs. The study was also supported by Focus Genetics and Linden Foods.

Trials took place on two upland flocks belonging to the Buccleuch Group and compared a typical UK production system of Mule and Texel x Mule ewes, with Highlander and Highlander x Blackface ewes to represent different replacement breeding strategies.

These ewes were crossed with Texel rams, to represent a typical UK terminal sire, as well as UK-bred and NZ-bred Primera rams. Performance was recorded throughout the production and processing cycle, finishing with an evaluation of meat-eating quality using consumer taste panels.

The trial concluded that increasing lamb output and production efficiency by switching from Mule to Highlander ewes offered the opportunity to develop a more sustainable lamb supply chain through reducing on farm costs and greenhouse gas emissions, whilst maintaining product quality, processing efficiency and meat eating quality. Replacing Texel rams with Primera resulted in faster growth rates and a higher proportion of high-value cuts.

Commenting on the results of the trial, AFBI scientist, Dr Ronald Annett, said: "The Highlander ewe showed excellent fertility and rearing ability and the Primera-sired lambs portrayed superior growth rates and had higher wholesale value." "Hopefully this study will make UK farmers think about what drives their returns. It highlights the importance of production efficiency, rather than focusing solely on lamb price or carcass conformation. The trial has demonstrated the importance of maternal genetics in driving production and we hope farmers will take this on board."

Steve McLean, Head of Agriculture & Fisheries Sourcing at M&S, added:

"For a number of years commercial volatility has seen increasing numbers of sheep producers leaving the industry in the UK. We commissioned this work as one of our PaceSetter projects within our Farming for the Future programme. Over the last seven years we have worked with Focus Genetics and a number of UK farmers to try to replicate their successful New Zealand lamb production model in the UK. "We recognise that there are a large number of different production systems in the UK and this trial is simply about establishing baseline information to allow producers to make their own informed decisions on the production model that best suits their farm."

Bayden Wilson, Focus Genetics UK Manager, concluded:

"We welcome the results of the study and hope it will encourage more UK farmers to invest in Focus Genetics breeds. We would like to grow our UK business and we hope farmers will convert after seeing such positive scientific results from New Zealand sheep breeds. As the world seeks more sustainable food production, our genetics are obviously well placed to help farmers improve on-farm efficiency."

See the article here:
NZ sheep genetics could improve UK sheep industry - research

Recommendation and review posted by Bethany Smith

Gene Therapy for Eye Diseases - Dr. Donald J. D #39;Amico
Donald J. D #39;Amico, MD, the Ophthalmologist-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center, talks about gene therapy as a potential treatment for eye diseases. You can learn more about Dr. D #39;Amico at: nyp.orgFrom:newyorkpresbyterianViews:0 0ratingsTime:01:55More inScience Technology

See the article here:
Gene Therapy for Eye Diseases - Dr. Donald J. D'Amico - Video

Recommendation and review posted by Bethany Smith

SILVER SPRING, Md., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today its subsidiary Austrianova Singapore (ASPL) has published a new manuscript that describes the use of the Company's proprietary cell encapsulation technology for studies designed to create a cell based therapeutic treatment for diabetes.

The publication in the Wiener Medizinische Wochenschrift Skriptum, entitled "Cell encapsulation for the treatment of diabetes" was co-authored with Dr. Eva Brandtner, former ASPL Chief Scientific Officer who is presently at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) in Austria. The manuscript outlines the advantages of using cellulose sulfate for the encapsulation of cells for treatment of diabetes. The article accompanied an invited presentation on the same topic at the Diabetes Meeting in Salzburg, Austria also given by Dr. Brandtner.

ASPL and VIVIT have planned and are working closely together to advance and develop the diabetes treatment using encapsulated cells capable of expressing insulin after they detect the presence of glucose. Ultimately, the aim is to place insulin-secreting cells encapsulated in cellulose sulphate in patients with diabetes to replace the patient's own cells that no longer secrete insulin in response to elevated levels of glucose. As a result, the encapsulated cells thereby replace the normal pancreatic cells and enable the body to function normally, preventing exposure to the debilitating effects of high levels of glucose in the body.

The CEO of ASPL, Dr. Brian Salmons, said, "We are very happy to have been able to release our data through this publication from our testing of the encapsulated live cell treatment potential for diabetes. Being able to continue our work with VIVIT and Dr. Eva Brandtner, will greatly enhance our ability to develop and advance diabetes treatments."

The President and CEO of Nuvilex, Dr. Robert Ryan, stated "Our commitment to create valuable patient treatments through the proprietary cell encapsulation developed over so many years by ASPL, including treatments for diabetes, has become stronger over the past year. The important advances made have been through the funding provided by Nuvilex this past year and will prove valuable in the coming years. Clearly the ability to treat patients with this disease is a major driving force for our companies. From a market perspective, the World Health Organization has shown that the economic benefits will be substantial as the costs of diabetes are presently estimated to be over $350 Billion dollars spent annually per year worldwide."

About Nuvilex

Nuvilex, Inc. (NVLX) is an international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Important advances are moving Nuvilex and Austrianova Singapore forward. New developments by our company and subsidiaries will be substantial as we have been working on many fronts to move us forward. We hope to bring some of these to light very soon. Our company's clinical offerings will include cancer, diabetes and other treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

Original post:
Nuvilex Subsidiary, Austrianova Singapore, Publishes Advantages of its Encapsulated Cell Therapy for the Cell-Based ...

Recommendation and review posted by Bethany Smith

AMSTERDAM, The Netherlands, December 5, 2012 /PRNewswire/ --

uniQure B.V., a leader in the field of human gene therapy, today announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. (BLT.AX) giving uniQure access to Benitec's proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington's disease. In return, uniQure granted Benitec non-exclusive access to the Company's AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B.

"The cross-licensing agreement with Benitec fully capitalizes on the strength of our advanced AAV platform and our proven ability to deliver therapeutic genes to target cells with high accuracy and efficacy," says Jrn Aldag, CEO of uniQure. "The agreement with Benitec opens up promising new avenues to develop therapies for high unmet medical needs such as Huntington's disease. While our current programs focus on delivering fully functioning therapeutic genes to remedy faulty or malfunctioning genes, Benitec's ddRNAi technology will allow us to do the opposite - to 'silence' the gene responsible for producing the mutant protein that lies at the basis of Huntington's disease, and to develop a therapy for this devastating disease."

Dr Peter French, CEO of Benitec Biopharma, commented, "Benitec Biopharma is very pleased to have executed this licensing agreement with uniQure, the first company to achieve market approval for a gene therapy product, Glybera, in the West. uniQure have demonstrated their unique ability to take gene therapy-based programs from pre-clinical stages to commercialization, and we are confident that they will be able to achieve a similar outcome in this program. Importantly this agreement also provides Benitec access to uniQure's AAV delivery technology enabling further development of our ddRNAi treatment for Hepatitis B."

About Huntington's disease

Huntington's disease (HD) is a rare, chronic, incurable, progressive and disabling neurological condition, which continues to challenge the medical community. About 30,000 Americans (or 1 in 10,000 people) have Huntington's disease and at least 150,000 individuals have a 50% chance of inheriting the disease. The symptoms of HD become most evident in adulthood, typically 30 to 55 years, characterized by sudden, abnormal, and uncontrolled jerky movements called chorea. Currently, therapeutics for HD are limited only to symptomatic treatments and there are no treatment options with proven safety and efficacy to slow down disease progression or enhance survival rate.

About uniQure

uniQure is a world leader in the development ofhuman gene based therapies.uniQure's Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency has been approved in the European Union, and is the first approved gene therapy in the Western world. uniQure's product pipeline of gene therapy products in development comprise hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform.This proprietary platform can be applied to a large number of rare(orphan) diseases caused by one faulty gene, and allows uniQure to pursue its strategy of focusing on this sector of the industry. uniQure's largest shareholders are Forbion Capital Partners and Gilde Healthcare, two of the leading life sciences venture capital firms in the Netherlands. Further information can be found at http://www.uniqure.com.

About Benitec Biopharma

Benitec Biopharma Ltd is developing novel treatments for chronic and life-threatening conditions based on targeted gene-silencing activity using a transformational technology: DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and to cure disease results from its demonstrated ability to permanently silence genes which cause the condition. Importantly, this technology's target gene and related gene pathways will rarely have presented as a therapeutic avenue for research for the traditional small molecule agents, currently accounting for the majority of today's pharmaceutical products.

See more here:
uniQure Licenses RNA Interference Technology to Advance Huntington's Disease Program

Recommendation and review posted by Bethany Smith

AMSTERDAM, The Netherlands, December 6, 2012 /PRNewswire/ --

uniQure B.V., a leader in the field of human gene therapy, today announced the appointment of Hans Christian Rohde as Chief Commercial Officer.

Mr. Rohde joins uniQure from Basilea Pharmaceutica (SIX:BSLN) where from 2007 he was Chief Commercial Officer and member of the company's executive management committee with responsibility for global commercial operations, marketing, supply chain, medical affairs, pricing and market access.

"We are very pleased with Hans Christian's appointment," says Jrn Aldag, CEO of uniQure. "With the approval of Glybera we need to rapidly build and expand our commercial organization to enable the successful roll-out of Glybera and provide access to this crucial treatment to as many patients as possible. Hans Christian's experience and successful track-record in major biotechnology companies such as Basilea, Merck-Serono and Biogen Idec provide us with the necessary leadership qualities to successfully commercialize Glybera."

Hans Christian Rohde (M.Sc., MBA) has almost 25 years experience in commercial roles at leading biotechnology and pharmaceutical companies. Prior to Basilea Pharmaceutica, Mr. Rohde was Corporate Vice President, Head of Global Therapeutic Areas Reproductive Health and Endocrinology at Merck-Serono from 2003 until 2007. Before this he was responsible for international marketing and global market development at Biogen Idec. From 1992 until 2000, Mr Rohde held positions of increasing commercial responsibility at Novo Nordisk. Mr. Rohde started his career at Laboratoires Syntex.

About uniQure

uniQure is a world leader in the development ofhuman gene based therapies.uniQure's Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency has been approved in the European Union, and is the first approved gene therapy in the Western world. uniQure's product pipeline of gene therapy products in development comprise hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform.This proprietary platform can be applied to a large number of rare(orphan) diseases caused by one faulty gene. uniQure's largest shareholders are Forbion Capital Partners and Gilde Healthcare, two of the leading life sciences venture capital firms in the Netherlands. Further information can be found at http://www.uniqure.com.

About Glybera

uniQure has developed Glybera as a therapy for patients with the genetic disorder lipoprotein lipase deficiency, an orphan disease. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL enzyme in patients. This enzyme is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating complication of LPLD. Glybera has orphan drug designation in the EU and US, and obtained marketing authorisation from the European Commission for commercialization in the 27 EU countries in November, 2012, making it the first gene therapy to win approval in the Western world.

Original post:
uniQure Appoints Hans Christian Rohde Chief Commercial Officer

Recommendation and review posted by Bethany Smith

Kell - ASD - 3 day after Stem Cell Treatment Part 2
For more information about ASD and Stem Cell Therapy, please visit worldstemcells.com 2012 World Stem Cells LLCFrom:WorldStem CellsViews:2 2ratingsTime:17:14More inScience Technology

Read the original post:
Kell - ASD - 3 day after Stem Cell Treatment Part 2 - Video

Recommendation and review posted by simmons

Making Stem Cell Thearpy Safer - Mayo Clinic
Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult tissues to have properties of embryonic stem cells, which have the unlimited capacity to differentiate and grow into any desired types of cells, such as skin, brain, lung and heart cells. Study Author, Dr. Timothy Nelson provides and overview.From:mayoclinicViews:46 0ratingsTime:02:04More inScience Technology

See the original post here:
Making Stem Cell Thearpy Safer - Mayo Clinic - Video

Recommendation and review posted by simmons

Stephen Quake, 2012 Lemelson-MIT Prize Winner
Dr. Stephen Quake, one of the world #39;s most prolific inventors, was recipient of the 2012 $500000 Lemelson-MIT Prize. An adventurer at heart, Quake relishes in the adrenaline that comes from mountain biking and ski mountaineering. It is that same rush he gets from exploring the unknown that drives him to consistently push scientific limits. Quake was recognized for his revolutionary work in drug discovery, genome analysis and personalized medicine.From:LemelsonMITProgramViews:1 0ratingsTime:04:37More inNonprofits Activism

See the original post here:
Stephen Quake, 2012 Lemelson-MIT Prize Winner - Video

Recommendation and review posted by sam

Kevin Krenitsky - How does a consumer find out about Foundation Medicine?
Kevin Krenitsky, Chief Operating Officer of Foundation Medicine sits down with Slone Partners at the Personalized Medicine Conference in Boston to discuss Foundation Medicine and their first clinical product, FoundationOne (www.foundationone.com). FoundationOne was released this year at ASCO (http and has since gained significant adoption in the industry. The 8th Annual Personalized Medicine Conference was hosted at Harvard Medical School by Partners Healthcare.From:SlonePartnersMediaViews:11 0ratingsTime:02:45More inScience Technology

See the original post here:
Kevin Krenitsky - How does a consumer find out about Foundation Medicine? - Video

Recommendation and review posted by sam

Kevin Krenitsky - Tell us about Foundation Medicine
Kevin Krenitsky, Chief Operating Officer of Foundation Medicine sits down with Slone Partners at the Personalized Medicine Conference in Boston to discuss Foundation Medicine and their first clinical product, FoundationOne (www.foundationone.com). FoundationOne was released this year at ASCO (http and has since gained significant adoption in the industry. The 8th Annual Personalized Medicine Conference was hosted at Harvard Medical School by Partners Healthcare.From:SlonePartnersMediaViews:9 0ratingsTime:03:34More inScience Technology

Excerpt from:
Kevin Krenitsky - Tell us about Foundation Medicine - Video

Recommendation and review posted by sam